Chadi checks in with Graham Collins, David Steensma, and Vincent Rajkumar to discuss the most prevalent and noteworthy clinical research from the EHA meeting for Hodgkin lymphoma, MDS and AML, multiple myeloma, and DLBCL.
In patients with relapsed or refractory multiple myeloma and soft -tissue plasmacytomas, an isatuximab-based regimen may significantly improve PFS and ORR with a manageable safety profile, according to new research.
Researchers demonstrated improved health-related quality of life for patients with heavily pretreated or renally impaired relapsed/refractory multiple myeloma after treatment with a combination regimen.
Researchers presenting at the European Hematology Association Virtual Meeting described the cumulative incidence of secondary malignancies resulting from treatment of Hodgkin lymphoma as well as risk factors for such malignancies.
A study presented at the European Hematology Association Virtual Meeting showed that BTK inhibitor therapy is effective for patients with heavily pretreated, high-risk CLL, including those with prior Richter transformation in remission.